Explicit hypoxia targeting with tumor suppression by creating an "obligate" anaerobic Salmonella Typhimurium strain

Scientific Reports

Volumn 2, Issue , 2012, Pages

  Yu, Bin ^a   Yang, Mei ^a,b   Shi, Lei ^a   Yao, Yandan ^b   Jiang, Qinqin ^a   Li, Xuefei ^c   Tang, Lei Han ^c   Zheng, Bo Jian ^a   Yuen, Kwok Yung ^a   Smith, David K ^d   Song, Erwei ^b   Huang, Jian Dong ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b SUN YAT SEN UNIVERSITY   (China)

^c HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^d Labyrinth Bioinformatics and Education ^*  (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; VNP 20009;

ANAEROBIC BACTERIUM; ANIMAL; ANOXIA; ARTICLE; BIOLOGICAL THERAPY; BREAST TUMOR; DRUG EFFECT; DRUG SCREENING; FEMALE; GENETIC ENGINEERING; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; METHODOLOGY; MICROBIOLOGY; MOUSE; NEOPLASM; NUDE MOUSE; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; SALMONELLA TYPHIMURIUM; TUMOR CELL LINE; TUMOR VOLUME; VIRULENCE;

ANIMALS; ANOXIA; BACTERIA, ANAEROBIC; BACTERIAL VACCINES; BIOLOGICAL THERAPY; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENETIC ENGINEERING; HOST-PATHOGEN INTERACTIONS; HUMANS; MICE; MICE, NUDE; NEOPLASMS; SALMONELLA TYPHIMURIUM; TUMOR BURDEN; VIRULENCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861860592     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep00436     Document Type: Article

References (49)

1. Brown, J. M. &Wilson, W. R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4, 437-447 (2004). (Pubitemid 38745529)
2. Zhou, J., Schmid, T., Schnitzer, S. & Brune, B. Tumor hypoxia and cancer progression. Cancer Lett 237, 10-21 (2006).
3. Pawelek, J., Low, K. & Bermudes, D. Bacteria as tumour-targeting vectors. Lancet Oncol 4, 548-556 (2003). (Pubitemid 38351712)
4. St Jean, A. T., Zhang, M. & Forbes, N. S. Bacterial therapies: completing the cancer treatment toolbox. Curr Opin Biotechnol 19, 511-517 (2008).
5. Kasinskas, R. W. & Forbes, N. S. Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro. Biotechnol Bioeng 94, 710-721 (2006). (Pubitemid 44014201)
6. Wei, M. Q., Ren, R., Good, D. & Anne, J. Clostridial spores as live 'Trojan horse' vectors for cancer gene therapy: comparison with viral delivery systems. Genet Vaccines Ther 6, 8 (2008).
7. Kong, W. et al. Regulated programmed lysis of recombinant Salmonella in host tissues to release protective antigens and confer biological containment. PNAS 105, 9361-9366 (2008).
8. Wei, M. Q. et al. Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours. Eur J Cancer 43, 490-496 (2007). (Pubitemid 46177582)
9. Dang, L. H., Bettegowda, C., Huso, D. L., Kinzler, K. W. & Vogelstein, B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U S A 98, 15155-15160 (2001). (Pubitemid 34013985)
10. Hall, S. S. A commotion in the blood : life, death, and the immune system, Edn. 1st. (Henry Holt, New York, 1997).
11. Leschner, S.&Weiss, S. Salmonella-allies in the fight against cancer. JMol Med 88, 763-773 (2010).
12. Sasaki, T. et al. Genetically engineered Bifidobacterium longum for tumortargeting enzyme-prodrug therapy of autochthonous mammary tumors in rats. Cancer Sci 97, 649-657 (2006). (Pubitemid 44056614)
13. Yazawa, K., Fujimori, M., Amano, J., Kano, Y. & Taniguchi, S. Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors. Cancer Gene Ther 7, 269-274 (2000). (Pubitemid 30194562)
14. Yazawa, K. et al. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat 66, 165-170 (2001). (Pubitemid 32521423)
15. Barbe, S., Van Mellaert, L. & Anne, J. The use of clostridial spores for cancer treatment. J Appl Microbiol 101, 571-578 (2006). (Pubitemid 44222287)
16. Van Mellaert, L., Barbe, S. & Anne, J. Clostridium spores as anti-tumour agents. Trends Microbiol 14, 190-196 (2006).
17. Liu, S. C., Minton, N. P., Giaccia, A. J. & Brown, J. M. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther 9, 291-296 (2002). (Pubitemid 34256904)
18. Theys, J. et al. Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo. Br J Cancer 95, 1212-1219 (2006). (Pubitemid 44658485)
19. Liu, S. C. et al.Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104. Cancer Res 68, 7995-8003 (2008).
20. Pawelek, J. M., Low, K. B. & Bermudes, D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 57, 4537-4544 (1997). (Pubitemid 27441058)
21. Low, K. B. et al. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol 17, 37-41 (1999). (Pubitemid 29037207)
22. Kasinskas, R. W. & Forbes, N. S. Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis. Cancer Res 67, 3201-3209 (2007). (Pubitemid 46724858)
23. Nguyen, V. H. et al. Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer. Cancer Res 70, 18-23 (2010).
24. Zhao, M. et al. Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res 66, 7647-7652 (2006). (Pubitemid 44289222)
25. Hayashi, K. et al. Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium. J Cell Biochem 106, 992-998 (2009).
26. Yam, C. et al. Monotherapy with a Tumor-Targeting Mutant of S. typhimurium Inhibits Liver Metastasis in a Mouse Model of Pancreatic Cancer. J Surg Res (2009).
27. Zhao, M. et al. Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci U S A 104, 10170-10174 (2007). (Pubitemid 47175281)
28. Hoiseth, S. K. & Stocker, B. A. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 291, 238-239 (1981). (Pubitemid 11081517)
29. Forbes, N. S., Munn, L. L., Fukumura, D. & Jain, R. K. Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors. Cancer Res 63, 5188-5193 (2003). (Pubitemid 37139825)
30. Leschner, S. et al. Tumor invasion of Salmonella enterica serovar Typhimurium is accompanied by strong hemorrhage promoted by TNF-alpha. PLoS One 4, e6692 (2009).
31. Loessner, H. et al. Remote control of tumour-targeted Salmonella enterica serovar Typhimurium by the use of L-arabinose as inducer of bacterial gene expression in vivo. Cell Microbiol 9, 1529-1537 (2007). (Pubitemid 46774023)
32. Royo, J. L. et al. In vivo gene regulation in Salmonella spp. by a salicylatedependent control circuit. Nat Methods 4, 937-942 (2007). (Pubitemid 350042383)
33. Westphal, K., Leschner, S., Jablonska, J., Loessner, H. &Weiss, S. Containment of tumor-colonizing bacteria by host neutrophils. Cancer Res 68, 2952-2960 (2008). (Pubitemid 351556296)
34. Clairmont, C. et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infect Dis 181, 1996-2002 (2000). (Pubitemid 30416163)
35. Friedlos, F. et al. Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 tomousemelanoma and human breast and colon carcinomas for effective suicide gene therapy. Clin Cancer Res 14, 4259-4266 (2008).
36. Jia, L. J. et al. Oral delivery of tumor-targeting Salmonella for cancer therapy in murine tumor models. Cancer Sci 98, 1107-1112 (2007).
37. Heimann, D. M. & Rosenberg, S. A. Continuous intravenous administration of live genetically modified salmonella typhimurium in patients with metastatic melanoma. J Immunother 26, 179-180 (2003). (Pubitemid 36292789)
38. Toso, J. F. et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 20, 142-152 (2002). (Pubitemid 34032605)
39. Zhao,M. et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFPexpressing Salmonella typhimurium. Proc Natl Acad Sci U S A 102, 755-760 (2005). (Pubitemid 40282738)
40. Song, M. et al. ppGpp-dependent stationary phase induction of genes on Salmonella pathogenicity island 1. J Biol Chem 279, 34183-34190 (2004). (Pubitemid 39318041)
41. Arrach, N. et al.High-throughput screening for salmonella avirulent mutants that retain targeting of solid tumors. Cancer Res 70, 2165-2170 (2010).
42. 2+ Cluster Switch in the Transcriptional Regulator FNR. J. AM. CHEM. SOC. 130, 1749-1758 (2008). (Pubitemid 351214096)
43. Mengesha, A. et al. Development of a Flexible and Potent Hypoxia-Inducible Promoter for Tumor-Targeted Gene Expression in Attenuated Salmonella. Cancer Biology & Therapy 5, 1120-1128 (2006). (Pubitemid 44772225)
44. Boysen, A., Moller-Jensen, J., Kallipolitis, B., Valentin-Hansen, P. & Overgaard, M. Translational regulation of gene expression by an anaerobically induced small non-coding RNA in Escherichia coli. J Biol Chem 285, 10690-10702 (2010).
45. Rainey, P. B. & Preston, G. M. In vivo expression technology strategies: valuable tools for biotechnology. Curr Opin Biotechnol 11, 440-444 (2000).
46. Heap, J. T. et al. The ClosTron: Mutagenesis in Clostridium refined and streamlined. J Microbiol Methods 80, 49-55 (2010).
47. Yu, B. et al. A method to generate recombinant Salmonella typhi Ty21a strains expressing multiple heterologous genes using an improved recombineering strategy. Appl Microbiol Biotechnol 91, 177-188 (2011).
48. Datta, S., Costantino, N. & Court, D. L. A set of recombineering plasmids for gram-negative bacteria. Gene 379, 109-115 (2006). (Pubitemid 44247330)
49. Animal Research Advisory Committee. Guidelines for Endpoints in Animal Study Proposals. http://oacu.od.nih.gov/ARAC/documents/ASP-Endpoints.pdf (2011).